FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155216449> ?p ?o ?g. }

• W3155216449 abstract "Abstract Background Angiogenic factors are commonly activated in solid tumors and present a viable therapeutic target. However, anticancer treatment with angiogenesis inhibitors (AGI) is limited to a few cancers, mostly as monotherapy and not selected based on molecular indications. We aimed to determine whether patient-specific combination regimens with AGI and other anticancer agents when selected based on multi-analyte tumor interrogation (ETA: Encyclopedic Tumor Analysis) can expand the scope of AGIs in advanced refractory solid organ cancers with improved treatment responses. Methods We evaluated treatment outcomes in 60 patients with advanced, refractory solid organ cancers who received ETA-guided combination regimens of AGI with other targeted, endocrine or cytotoxic agents. Radiological evaluation of treatment response was followed by determination of Objective Response Rate (ORR), Disease Control Rate (DCR), Progression Free Survival (PFS) and Overall Survival (OS). Results Among the 60 patients, Partial Response (PR) was observed in 28 cases (46.7%), Stable Disease (SD) was observed in 29 cases (48.3%) and Disease Progression (PD, within 60 days) was observed in 3 cases (5.0%). The ORR was 46.7% and DCR was 95.0%. At the most recent follow, up the median PFS (mPFS) was 5.0 months and median OS (mOS) was 8.9 months. There were no Grade 4 therapy related adverse events or treatment related deaths. Conclusions ETA-guided patient-specific combination regimens with AGI and other anti-neoplastic agents, can yield improved outcomes over AGI monotherapy. Trial Registration Details of all trials are available at WHO-ICTRP: https://apps.who.int/trialsearch/. RESILIENT ID CTRI/2018/02/011808. LIQUID IMPACT ID CTRI/2019/02/017548." @default.
• W3155216449 created "2021-04-26" @default.
• W3155216449 creator A5007043144 @default.
• W3155216449 creator A5009096856 @default.
• W3155216449 creator A5015926221 @default.
• W3155216449 creator A5029096381 @default.
• W3155216449 creator A5040086715 @default.
• W3155216449 creator A5047835983 @default.
• W3155216449 creator A5047983896 @default.
• W3155216449 creator A5051272739 @default.
• W3155216449 creator A5053301219 @default.
• W3155216449 creator A5054331333 @default.
• W3155216449 creator A5056293873 @default.
• W3155216449 creator A5057697338 @default.
• W3155216449 creator A5063125893 @default.
• W3155216449 creator A5069922846 @default.
• W3155216449 creator A5077401088 @default.
• W3155216449 creator A5087494976 @default.
• W3155216449 creator A5087680459 @default.
• W3155216449 date "2021-03-31" @default.
• W3155216449 modified "2023-09-27" @default.
• W3155216449 title "Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers" @default.
• W3155216449 cites W1523079887 @default.
• W3155216449 cites W1543678657 @default.
• W3155216449 cites W1971837077 @default.
• W3155216449 cites W2019607817 @default.
• W3155216449 cites W2023952988 @default.
• W3155216449 cites W2026996188 @default.
• W3155216449 cites W2035743945 @default.
• W3155216449 cites W2055437192 @default.
• W3155216449 cites W2067216473 @default.
• W3155216449 cites W2074306827 @default.
• W3155216449 cites W2079150475 @default.
• W3155216449 cites W2082806449 @default.
• W3155216449 cites W2101776780 @default.
• W3155216449 cites W2104607769 @default.
• W3155216449 cites W2106465830 @default.
• W3155216449 cites W2116922255 @default.
• W3155216449 cites W2131862721 @default.
• W3155216449 cites W2138787512 @default.
• W3155216449 cites W2140765540 @default.
• W3155216449 cites W2147834058 @default.
• W3155216449 cites W2155789164 @default.
• W3155216449 cites W2158474413 @default.
• W3155216449 cites W2161579181 @default.
• W3155216449 cites W2162424705 @default.
• W3155216449 cites W2164308593 @default.
• W3155216449 cites W2166573361 @default.
• W3155216449 cites W2168076926 @default.
• W3155216449 cites W2269193243 @default.
• W3155216449 cites W2301695049 @default.
• W3155216449 cites W2396218464 @default.
• W3155216449 cites W2482216880 @default.
• W3155216449 cites W2506963569 @default.
• W3155216449 cites W2530419161 @default.
• W3155216449 cites W2560499218 @default.
• W3155216449 cites W2606533981 @default.
• W3155216449 cites W2787695357 @default.
• W3155216449 cites W2789740887 @default.
• W3155216449 cites W2802380482 @default.
• W3155216449 cites W2907995446 @default.
• W3155216449 cites W2936300667 @default.
• W3155216449 cites W2941109595 @default.
• W3155216449 cites W2953807946 @default.
• W3155216449 cites W2980372086 @default.
• W3155216449 cites W3007442940 @default.
• W3155216449 cites W3007953816 @default.
• W3155216449 cites W3008414152 @default.
• W3155216449 cites W3012052621 @default.
• W3155216449 cites W3028725009 @default.
• W3155216449 cites W3084289412 @default.
• W3155216449 cites W3111998801 @default.
• W3155216449 cites W3133255465 @default.
• W3155216449 cites W59047819 @default.
• W3155216449 cites W79301660 @default.
• W3155216449 cites W1569559112 @default.
• W3155216449 doi "https://doi.org/10.21203/rs.3.rs-356485/v1" @default.
• W3155216449 hasPublicationYear "2021" @default.
• W3155216449 type Work @default.
• W3155216449 sameAs 3155216449 @default.
• W3155216449 citedByCount "0" @default.
• W3155216449 crossrefType "posted-content" @default.
• W3155216449 hasAuthorship W3155216449A5007043144 @default.
• W3155216449 hasAuthorship W3155216449A5009096856 @default.
• W3155216449 hasAuthorship W3155216449A5015926221 @default.
• W3155216449 hasAuthorship W3155216449A5029096381 @default.
• W3155216449 hasAuthorship W3155216449A5040086715 @default.
• W3155216449 hasAuthorship W3155216449A5047835983 @default.
• W3155216449 hasAuthorship W3155216449A5047983896 @default.
• W3155216449 hasAuthorship W3155216449A5051272739 @default.
• W3155216449 hasAuthorship W3155216449A5053301219 @default.
• W3155216449 hasAuthorship W3155216449A5054331333 @default.
• W3155216449 hasAuthorship W3155216449A5056293873 @default.
• W3155216449 hasAuthorship W3155216449A5057697338 @default.
• W3155216449 hasAuthorship W3155216449A5063125893 @default.
• W3155216449 hasAuthorship W3155216449A5069922846 @default.
• W3155216449 hasAuthorship W3155216449A5077401088 @default.
• W3155216449 hasAuthorship W3155216449A5087494976 @default.
• W3155216449 hasAuthorship W3155216449A5087680459 @default.
• W3155216449 hasBestOaLocation W31552164491 @default.

• next